Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics, Inc.'s Q·Score is 7.8/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $36.88 is 57% above current price. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for ARQT is $36.88, based on ratings from 8 Wall Street analysts. This is 56.8% above the current price of $23.51. Price targets are forward-looking estimates and not guarantees of future performance.

Arcutis Biotherapeutics, Inc. (ARQT) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 18.0×. The consensus analyst price target of $36.88 is 57% above the current price.

Arcutis Biotherapeutics, Inc.'s next earnings report is expected on approximately October 27, 2026.

Arcutis Biotherapeutics, Inc. has a net profit margin of 6.1%, which is positive but relatively thin. Its gross margin stands at 91.1%, indicating a high-margin business model.

Arcutis Biotherapeutics, Inc. is reporting strong year-over-year growth of 59.3%.

Arcutis Biotherapeutics, Inc. has a debt-to-equity ratio of 0.52×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 2.92×, indicating comfortable short-term liquidity.